44 – Cancer of the Bladder

[1]  R. Sylvester,et al.  Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  T. Guzzo,et al.  Hydronephrosis is an independent predictor of poor clinical outcome in patients treated for muscle-invasive transitional cell carcinoma with radical cystectomy. , 2008, Urology.

[3]  C. Chapple,et al.  Anatomy of the lower urinary tract , 2008 .

[4]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[5]  P. Buffler,et al.  Personal use of hair dyes and risk of bladder cancer: a meta-analysis of epidemiologic data , 2008, Cancer Causes & Control.

[6]  J. Raman,et al.  Bladder cancer following upper tract urothelial carcinoma , 2008, Expert review of anticancer therapy.

[7]  E. Bergstralh,et al.  Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. , 2005, The Journal of urology.

[8]  C. Belka,et al.  Risk of Second Malignancies after Prostate Irradiation? , 2007, Strahlentherapie und Onkologie.

[9]  M. Knowles.  Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target , 2007, World Journal of Urology.

[10]  L. Blank,et al.  Results of bladder-conserving treatment, consisting of brachytherapy combined with limited surgery and external beam radiotherapy, for patients with solitary T1-T3 bladder tumors less than 5 cm in diameter. , 2007, International journal of radiation oncology, biology, physics.

[11]  J. Dunst,et al.  Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. , 2007, International journal of radiation oncology, biology, physics.

[12]  D. Parekh,et al.  Urinary diversion: options, patient selection, and outcomes. , 2007, Seminars in oncology.

[13]  A. Horwich,et al.  A feasibility study of using gold seeds as fiducial markers for bladder localization during radical radiotherapy. , 2007, The British journal of radiology.

[14]  P. Carroll,et al.  Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. , 2007, The Journal of urology.

[15]  Liang Cheng,et al.  Small-cell carcinoma of the urinary bladder: diagnosis and management , 2006, Expert review of anticancer therapy.

[16]  I. Gram,et al.  Tobacco smoke and bladder cancer—in the European prospective investigation into cancer and nutrition , 2006, International journal of cancer.

[17]  Ali Amer,et al.  Online adaptive radiotherapy of the bladder: small bowel irradiated-volume reduction. , 2006, International journal of radiation oncology, biology, physics.

[18]  Xiaocheng Wu,et al.  Annual report to the nation on the status of cancer, 1975–2003, featuring cancer among U.S. Hispanic/Latino populations , 2006, Cancer.

[19]  J. Gearhart,et al.  Standing the test of time: long-term outcome of reconstruction of the exstrophy bladder , 2006, World Journal of Urology.

[20]  R. Hautmann,et al.  Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. , 2005, The Journal of urology.

[21]  L. Collette,et al.  Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. , 2006, European journal of cancer.

[22]  Joseph Fontana,et al.  A single institution experience with concurrent capecitabine and radiation therapy in weak and/or elderly patients with urothelial cancer. , 2005, International journal of radiation oncology, biology, physics.

[23]  C. Vale.  Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration , 2005 .

[24]  S. Ricci,et al.  Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer , 2005 .

[25]  M. Etminan,et al.  Personal use of hair dyes and risk of cancer: a meta-analysis. , 2005, JAMA.

[26]  D. Dearnaley,et al.  A randomised trial of accelerated radiotherapy for localised invasive bladder cancer. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  F. Grémy,et al.  Bladder cancer and black tobacco cigarette smoking , 1994, European Journal of Epidemiology.

[28]  B. Jacobsen,et al.  Coffee and cancer: A prospective study of 43,000 Norwegian men and women , 1994, Cancer Causes & Control.

[29]  J. López,et al.  The value of tumour spread, grading and growth pattern as morphological predictive parameters in bladder carcinoma. A critical revision of the 1987 TNM classification , 2005, Journal of Cancer Research and Clinical Oncology.

[30]  H. von der Maase,et al.  Treatment outcome and prognostic variables for local control and survival in patients receiving radical radiotherapy for urinary bladder cancer , 2004, Acta oncologica.

[31]  B. Maciejewski,et al.  Clinical radiobiology of stage T2-T3 bladder cancer. , 2004, International journal of radiation oncology, biology, physics.

[32]  H. von der Maase,et al.  Long-term bladder, colorectal, and sexual functions after radical radiotherapy for urinary bladder cancer. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[33]  H. Grossman,et al.  Surgical factors influence bladder cancer outcomes: a cooperative group report. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  David C. Smith,et al.  Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Chin,et al.  Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. , 2004, The Journal of urology.

[36]  V. Khoo,et al.  Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. , 2002, International journal of radiation oncology, biology, physics.

[37]  R. Goldbohm,et al.  Are Coffee, Tea, and Total Fluid Consumption associated with Bladder Cancer Risk? Results from the Netherlands Cohort Study , 2004, Cancer Causes & Control.

[38]  R. Wahl,et al.  Preliminary assessment of fluorine-18 fluorodeoxyglucose positron mission tomography in patients with bladder cancer , 1997, European Journal of Nuclear Medicine.

[39]  N. Weiss.  Cancer in relation to occupational exposure to perchloroethylene , 1995, Cancer Causes & Control.

[40]  L. Muren,et al.  Organ motion, set-up variation and treatment margins in radical radiotherapy of urinary bladder cancer. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[41]  John D. Roberts,et al.  RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. , 2003, International journal of radiation oncology, biology, physics.

[42]  A. Zietman,et al.  Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. , 2003, The Journal of urology.

[43]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[44]  S. Groshen,et al.  Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. , 2003, The Journal of urology.

[45]  K. Czene,et al.  Cancer risks in hairdressers: Assessment of carcinogenicity of hair dyes and gels , 2003, International journal of cancer.

[46]  H. Sandler,et al.  Overview of bladder cancer trials in the Radiation Therapy Oncology Group , 2003, Cancer.

[47]  M. Hulshof,et al.  Influence of bladder and rectal volume on spatial variability of a bladder tumor during radical radiotherapy. , 2003, International journal of radiation oncology, biology, physics.

[48]  F. Burkhard,et al.  Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  H. Herr.  Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy. , 2003, Urology.

[50]  A. Böhle,et al.  Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. , 2003, The Journal of urology.

[51]  A. Kuten,et al.  Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer , 2002, Journal of surgical oncology.

[52]  S. Tannenbaum,et al.  Arylamine exposures and bladder cancer risk. , 2002, Mutation research.

[53]  J. Dunst,et al.  Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  A. Zietman,et al.  Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. , 2002, Urology.

[55]  A. Zietman,et al.  Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. , 2001, Urology.

[56]  R. Perez,et al.  Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. , 2001, International journal of radiation oncology, biology, physics.

[57]  H. Moch,et al.  Molecular cytogenetic alterations associated with rapid tumor cell proliferation in advanced urinary bladder cancer. , 2001, International journal of oncology.

[58]  C. Woodhouse,et al.  Neoplasia in adult exstrophy patients , 2001, BJU international.

[59]  S R Tannenbaum,et al.  Gender- and smoking-related bladder cancer risk. , 2001, Journal of the National Cancer Institute.

[60]  C. Busch,et al.  Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. , 2001, The Journal of urology.

[61]  Mimi C. Yu,et al.  Use of permanent hair dyes and bladder‐cancer risk , 2001, International journal of cancer.

[62]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  H. Grossman,et al.  Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. , 2001, The Journal of urology.

[64]  J. Baselga,et al.  A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. , 2001, European journal of cancer.

[65]  W. Huang,et al.  Single agent paclitaxel as a first-line therapy in advanced urothelial carcinoma: its efficacy and safety in patients even with pretreatment renal insufficiency. , 2000, Japanese journal of clinical oncology.

[66]  L. True,et al.  The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. , 2000, The oncologist.

[67]  P. Albers,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  J. Baselga,et al.  Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  D. Vaughn.  Paclitaxel and carboplatin in bladder cancer: recent developments. , 2000, European journal of cancer.

[70]  J. Carles,et al.  Carboplatin-Gemcitabine Treatment of Patients with Transitional Cell Carcinoma of the Bladder and Impaired Renal Function , 2000, Oncology.

[71]  S. Fosså,et al.  A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09. , 2000, International journal of radiation oncology, biology, physics.

[72]  C. Hutchinson,et al.  Relationship of MRI and clinical staging to outcome in invasive bladder cancer treated by radiotherapy. , 2000, Clinical radiology.

[73]  N. Rothman,et al.  NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. , 2000, Pharmacogenetics.

[74]  D. Neal,et al.  A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. , 2000, The Journal of urology.

[75]  M. Mazumdar,et al.  Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  G. Griffiths.  Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists , 1999 .

[77]  B. Donnelly,et al.  Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of radiation therapy oncology group 89-03. , 1998, The Journal of urology.

[78]  Lawrence D. True,et al.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder , 1998 .

[79]  K. Steven,et al.  Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. , 1998, The Journal of urology.

[80]  M. Dimopoulos,et al.  Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel. , 1998, Urology.

[81]  P. Hall,et al.  Risk of second malignant neoplasms among long-term survivors of testicular cancer. , 1997, Journal of the National Cancer Institute.

[82]  I. Tannock,et al.  Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  C. Goodman,et al.  Microscopic haematuria: urological investigation using a standard protocol. , 1996, British journal of urology.

[84]  I. Tannock,et al.  Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  W. See,et al.  Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. , 1996, The Journal of urology.

[86]  P. Carroll,et al.  A carboplatin‐based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium , 1996, Cancer.

[87]  R. Wahlqvist,et al.  Five-year Followup of a Prospective Trial of Radical Cystectomy and Neoadjuvant Chemotherapy: Nordic Cystectomy Trial 1 , 1996 .

[88]  A. Pollack,et al.  Radiotherapy for stage T3b transitional cell carcinoma of the bladder. , 1996, Seminars in urologic oncology.

[89]  A. Zietman,et al.  Combined modality treatment with selective bladder conservation for invasive bladder cancer: long-term tolerance in the female patient. , 1996, The cancer journal from Scientific American.

[90]  F. Freiha,et al.  A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. , 1996, The Journal of urology.

[91]  S. Mondillo,et al.  Comparison between a cisplatin‐containing regimen and a carboplatin‐containing regimen for recurrent or metastatic bladder cancer patients: A randomized phase II study , 1996, Cancer.

[92]  L. True,et al.  Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  P. Bassi,et al.  Is stage pT4a (D1) reliable in assessing transitional cell carcinoma involvement of the prostate in patients with a concurrent bladder cancer? A necessary distinction for contiguous or noncontiguous involvement. , 1996, The Journal of urology.

[94]  C. Kwoh,et al.  Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. , 1995, Arthritis and rheumatism.

[95]  P. Sparén,et al.  Second primary cancer after treatment for cervical cancer. An international cancer registries study , 1995, Cancer.

[96]  T. Polascik,et al.  Novel suppressor loci on chromosome 14q in primary bladder cancer. , 1995, Cancer research.

[97]  W. Benedict,et al.  The loss of retinoblastoma gene in association with c-myc and transforming growth factor-beta 1 gene expression in human bladder cancer. , 1995, The Journal of urology.

[98]  P. Carroll,et al.  Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. , 1995, The Journal of urology.

[99]  M. Álvarez-Mon,et al.  Use of intracavitary lnterferon‐alpha‐2b in the prophylactic treatment of patients with superficial bladder cancer , 1995 .

[100]  P. Lichter,et al.  Detection of chromosomal imbalances in transitional cell carcinoma of the bladder by comparative genomic hybridization. , 1995, The American journal of pathology.

[101]  S. Johansson,et al.  Primary small cell carcinoma of the bladder: a report of 25 cases. , 1995, The Journal of urology.

[102]  W. Fair,et al.  Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  C. Dinney,et al.  Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone. , 1995, International journal of radiation oncology, biology, physics.

[104]  M. Stratton,et al.  Mutations in the p53 gene in schistosomal bladder cancer: a study of 92 tumours from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumours. , 1995, Carcinogenesis.

[105]  P. Carroll,et al.  Chromosome‐9 loss detected by fluorescence in situ hybridization in bladder cancer , 1995, International journal of cancer.

[106]  C. Cordon-Cardo,et al.  Tumor suppressor gene alterations in bladder carcinoma. Translational correlates to clinical practice. , 1995, Surgical Oncology Clinics of North America.

[107]  T. Uchida,et al.  p53 mutations and prognosis in bladder tumors. , 1995, The Journal of urology.

[108]  M. Harada,et al.  Numerical chromosome aberrations in bladder cancer detected by in situ hybridization. , 1995, British journal of urology.

[109]  B. Armstrong,et al.  Estimation of risk of developing bladder cancer among workers exposed to coal tar pitch volatiles in the primary aluminum industry. , 1995, American journal of industrial medicine.

[110]  S. Devries,et al.  Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization , 1995, Genes, chromosomes & cancer.

[111]  P. O'connor,et al.  Role of schistosomiasis in human bladder cancer: evidence of association, aetiological factors, and basic mechanisms of carcinogenesis. , 1995, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[112]  J. Miskowiak,et al.  Results of radiotherapy on ureteric obstruction in muscle-invasive bladder cancer. , 1995, British journal of urology.

[113]  R. Hattori,et al.  Detection of muscle layer invasion with submillimeter pixel MR images: staging of bladder carcinoma. , 1995, Magnetic resonance imaging.

[114]  T. Sorahan,et al.  Urolthelial cancer and cigarette smoking: findings from a regional case‐controlled study , 1994 .

[115]  D. Neal,et al.  c-jun oncogene expression in transitional cell carcinoma of the urinary bladder. , 1994, British journal of urology.

[116]  S. Fox,et al.  Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. , 1994, British journal of urology.

[117]  S C Chen,et al.  Accumulation of nuclear p53 and tumor progression in bladder cancer. , 1994, The New England journal of medicine.

[118]  E. Salminen,et al.  Bladder cancer and the risk of smoking-related cancers during followup. , 1994, The Journal of urology.

[119]  L. Skoog,et al.  Nonrandom numerical aberrations of chromosomes 7, 9, and 10 in DNA-diploid bladder cancer. , 1994, Cancer genetics and cytogenetics.

[120]  P. Vineis.  Epidemiology of cancer from exposure to arylamines. , 1994, Environmental health perspectives.

[121]  P. Carroll,et al.  Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. , 1994, Radiology.

[122]  R. Sauer,et al.  Organ-sparing treatment of advanced bladder cancer: a 10-year experience. , 1994, International journal of radiation oncology, biology, physics.

[123]  A. Pollack,et al.  Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors. , 1994, International journal of radiation oncology, biology, physics.

[124]  C. Cordon-Cardo,et al.  Altered patterns of MDM2 and TP53 expression in human bladder cancer. , 1994, Journal of the National Cancer Institute.

[125]  K. Yokota,et al.  Neoadjuvant intra-arterial doxorubicin chemotherapy in combination with low dose radiotherapy for the treatment of locally advanced transitional cell carcinoma of the bladder. , 1994, The Journal of urology.

[126]  C. Cordon-Cardo,et al.  Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. , 1994, The Journal of urology.

[127]  L. Mazzucchelli,et al.  Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. , 1994, The Journal of urology.

[128]  S. Fosså,et al.  Aims and results of palliative radiotherapy in urological cancer. , 1994, Current opinion in oncology.

[129]  D. Neal,et al.  Frequency of H-ras mutations in human bladder cancer detected by direct sequencing. , 1994, British journal of urology.

[130]  M. Rosin,et al.  Inflammation, chromosomal instability, and cancer: the schistosomiasis model. , 1994, Cancer research.

[131]  A. Sandberg,et al.  Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer. , 1994, The Journal of urology.

[132]  B. Vikram,et al.  A pilot study of chemotherapy alternating with twice-a-day accelerated radiation therapy as an alternative to cystectomy in muscle infiltrating (stages T2 and T3) cancer of the bladder: preliminary results. , 1994, The Journal of urology.

[133]  C. la Vecchia,et al.  Occupation and bladder cancer in Pordenone (north-east Italy): a case-control study. , 1994, International Journal of Epidemiology.

[134]  R. Cote,et al.  Two molecular pathways to transitional cell carcinoma of the bladder. , 1994, Cancer research.

[135]  J. Siemiatycki,et al.  ARE THE APPARENT EFFECTS OF CIGARETTE SMOKING ON LUNG AND BLADDER CANCERS DUE TO UNCONTROLLED CONFOUNDING BY OCCUPATIONAL EXPOSURES? , 1994, Epidemiology.

[136]  I. Näslund,et al.  Hyperfractionated radiotherapy of bladder cancer. A ten-year follow-up of a randomized clinical trial. , 1994, Acta oncologica.

[137]  V. Srinivasan,et al.  A comparison of two radiotherapy regimens for the treatment of symptoms from advanced bladder cancer. , 1994, Clinical oncology (Royal College of Radiologists (Great Britain)).

[138]  R. Hayes,et al.  p53 mutations in human bladder cancer , 1994, Environmental and molecular mutagenesis.

[139]  M. Gospodarowicz.  Staging of bladder cancer. , 1994, Seminars in surgical oncology.

[140]  F. Bosman,et al.  Cytogenetic analysis in transitional cell carcinoma of the bladder. , 1993, British journal of urology.

[141]  J. Lemberger,et al.  Regression of transitional cell carcinoma of the bladder with radiotherapy: progression-free control in the bladder at 5 years. , 1993, Radiotherapy and Oncology.

[142]  W. Shipley,et al.  Selective bladder preservation by combination treatment of invasive bladder cancer. , 1993, The New England journal of medicine.

[143]  S. Groshen,et al.  p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. , 1993, The American journal of pathology.

[144]  F. Baillet,et al.  Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[145]  M. MoralesSuárez-Varela,et al.  Concentration of nitrates in drinking water and its relationship with bladder cancer. , 1993 .

[146]  C. Barton,et al.  Carboplatin-based chemotherapy for bladder cancer. , 1993, Cancer treatment reviews.

[147]  J. Reif,et al.  Case-control study of bladder cancer and water disinfection methods in Colorado. , 1993, American journal of epidemiology.

[148]  S. Fosså,et al.  Neoadjuvant chemotherapy in bladder cancer: a randomized study. Nordic Cystectomy Trial I. , 1993, Scandinavian journal of urology and nephrology.

[149]  C. Cordon-Cardo,et al.  Genetic alterations in bladder cancer , 1993, The Lancet.

[150]  T. Shirai.  Etiology of bladder cancer. , 1993, Seminars in urology.

[151]  Jack A. Taylor,et al.  Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. , 1993, Journal of the National Cancer Institute.

[152]  H. Anton-Culver,et al.  The association of bladder cancer risk with ethnicity, gender, and smoking. , 1993, Annals of epidemiology.

[153]  C. Viscoli,et al.  Bladder cancer and coffee drinking: a summary of case-control research , 1993, The Lancet.

[154]  I. Isherwood,et al.  Magnetic resonance imaging with Gadolinium-DTPA for assessment of bladder carcinoma and its response to treatment. , 1993, Clinical radiology.

[155]  A M Nomura,et al.  A prospective study of diet, smoking, and lower urinary tract cancer. , 1993, Annals of epidemiology.

[156]  E. Hammond,et al.  Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. , 1993, International journal of radiation oncology, biology, physics.

[157]  T. Čufer,et al.  Sequential transurethral surgery, multiple drug chemotherapy and radiation therapy for invasive bladder carcinoma: initial report. , 1993, International journal of radiation oncology, biology, physics.

[158]  M. Knowles,et al.  Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. , 1993, Oncogene.

[159]  K. Kuriyama,et al.  Bladder tumors: staging with gadolinium-enhanced oblique MR imaging. , 1993, Radiology.

[160]  C. Cordon-Cardo,et al.  Molecular Genetic Alterations of Chromosome 17 and p53 Nuclear Overexpression in Human Bladder Cancer , 1993, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[161]  H. Sandler,et al.  Treatment of T3a bladder cancer with iridium implantation. , 1993, Urology.

[162]  R. W. Morgan,et al.  Update on artificial sweeteners and bladder cancer. , 1993, Regulatory toxicology and pharmacology : RTP.

[163]  T. Nakada,et al.  Primary bladder pheochromocytoma without hypertension. , 1993, International urology and nephrology.

[164]  H. Wacker,et al.  Primary malignant melanoma of the bladder. A case report and literature review. , 1993, Urologia internationalis.

[165]  F. Tarhan,et al.  Rhabdomyosarcoma of the urinary bladder in an adult. , 1993, International urology and nephrology.

[166]  J. Kawamura,et al.  Leiomyosarcoma of the bladder eighteen years after cyclophosphamide therapy for retinoblastoma. , 1993, Urologia internationalis.

[167]  P. Lipponen.  Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer. , 1993, European journal of cancer.

[168]  A. Tanimoto,et al.  Bladder tumor staging: comparison of conventional and gadolinium-enhanced dynamic MR imaging and CT. , 1992, Radiology.

[169]  C. Fowler,et al.  The quality of life after radical radiotherapy for bladder cancer. , 1992, British journal of urology.

[170]  V. Leblond,et al.  [Primary bladder lymphoma in kidney transplant recipients: report of a case]. , 1992, Progrès en urologie (Paris).

[171]  J. Hopewell,et al.  A pilot study of accelerated fractionation in the radiotherapy of invasive carcinoma of the bladder. , 1992, The British journal of radiology.

[172]  M. Stöckle,et al.  Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. , 1992, The Journal of urology.

[173]  I. Tannock,et al.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[174]  W. Fair,et al.  Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. , 1992, The Journal of urology.

[175]  J. Chang-Claude,et al.  Life style and occupational risk factors for bladder cancer in Germany. A case‐control study , 1992, Cancer.

[176]  T. Sugimura,et al.  Frequent association of p53 gene mutation in invasive bladder cancer. , 1992, Cancer research.

[177]  L. Denis.  Clinical staging: its importance in therapeutic decisions and clinical trials. , 1992, Hematology/oncology clinics of North America.

[178]  P. Warde,et al.  The role of radiation therapy in the management of transitional cell carcinoma of the bladder. , 1992, Hematology/oncology clinics of North America.

[179]  W. Isaacs,et al.  Molecular biology of bladder cancer. , 1992, Hematology/oncology clinics of North America.

[180]  B. Stein,et al.  Superficial bladder cancer. , 1992, Hematology/oncology clinics of North America.

[181]  J. Richie.  Surgery for invasive bladder cancer. , 1992, Hematology/oncology clinics of North America.

[182]  A. Gerbaulet,et al.  Interstitial iridium-192 for bladder cancer (a multicentric survey: 205 patients). , 1992, International journal of radiation oncology, biology, physics.

[183]  D. Bostwick.  Natural history of early bladder cancer , 1992, Journal of cellular biochemistry. Supplement.

[184]  R. Hayes,et al.  Mortality and incidence of bladder cancer in benzidine-exposed workers in China. , 1992, American journal of industrial medicine.

[185]  E. Salminen.  Unconventional fractionation for palliative radiotherapy of urinary bladder cancer. A retrospective review of 94 patients. , 1992, Acta oncologica.

[186]  D. Silverman,et al.  Bladder cancer and occupation in Shanghai, 1980-1984. , 1992, American journal of industrial medicine.

[187]  J. Williams,et al.  Bilateral hydronephrosis secondary to breast carcinoma metastasising to the bladder. , 1992, British journal of urology.

[188]  J. Freudenheim,et al.  Diet in the epidemiology of bladder cancer in western New York. , 1992, Nutrition and cancer.

[189]  D. Culkin,et al.  Bladder cancer in spinal cord injury patients. , 1991, The Journal of urology.

[190]  C. Cordon-Cardo,et al.  Molecular genetic alterations in superficial and locally advanced human bladder cancer. , 1991, Cancer research.

[191]  W. Shipley,et al.  Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[192]  P. Lipponen,et al.  Progression and survival in transitional cell bladder cancer: a comparison of established prognostic factors, S-phase fraction and DNA ploidy. , 1991, European journal of cancer.

[193]  A. Tanimoto,et al.  Efficacy of gadolinium-diethylenetriaminepentaacetic acid-enhanced magnetic resonance imaging for differentiation between superficial and muscle-invasive tumor of the bladder: a comparative study with computerized tomography and transurethral ultrasonography. , 1991, The Journal of urology.

[194]  J. Hankin,et al.  Dietary factors in cancer of the lower urinary tract , 1991, International journal of cancer.

[195]  F. Marshall,et al.  Adenocarcinoma of urinary bladder: classification and management. , 1991, Urology.

[196]  W. H. Kern,et al.  The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. , 1991, The Journal of urology.

[197]  E. Riboli,et al.  Urinary infection, renal lithiasis and bladder cancer in Spain. , 1991, European journal of cancer.

[198]  I. Näslund,et al.  Short-term radiotherapy as palliative treatment in patients with transitional cell bladder cancer. , 1991, British journal of urology.

[199]  F. Marshall,et al.  Local recurrence and survival following nerve-sparing radical cystoprostatectomy. , 1990, The Journal of urology.

[200]  C. Logothetis,et al.  A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[201]  N. Geller,et al.  Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse , 1989, Cancer.

[202]  S. Fosså,et al.  Phase II study of carboplatin in locally advanced and metastatic transitional cell carcinoma of the urinary bladder. , 1989, British journal of urology.

[203]  J. Herman,et al.  Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. , 1989, The Journal of urology.

[204]  W. Putten,et al.  Carcinoma of the urinary bladder category T2,3NXM0 treated by 40 Gy external irradiation followed by cesium137 implant at reduced dose (50%). , 1989 .

[205]  L. Eapen,et al.  Intraarterial cisplatin and concurrent radiation for locally advanced bladder cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[206]  P. Rubin,et al.  Tolerance of pelvic normal tissues to hyperfractionated radiation therapy: results of Protocol 83-08 of the Radiation Therapy Oncology Group. , 1988, International journal of radiation oncology, biology, physics.

[207]  M. Melamed,et al.  Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[208]  R. Dmochowski,et al.  Pelvic recurrence after radical cystectomy without preoperative radiation. , 1988, The Journal of urology.

[209]  A. Wein,et al.  Treatment of bladder cancer with interstitial iridium-192 implantation and external beam irradiation. , 1988, International journal of radiation oncology, biology, physics.

[210]  C. Abbou,et al.  Conservative treatment of bladder carcinoma by partial cystectomy and interstitial iridium 192. , 1987, International journal of radiation oncology, biology, physics.

[211]  E. Crawford,et al.  Preoperative radiation therapy in the treatment of bladder cancer. , 1987, The Urologic clinics of North America.

[212]  H. Herr,et al.  Conservative management of muscle-infiltrating bladder cancer: prospective experience. , 1987, The Journal of urology.

[213]  A. Einstein,et al.  Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. , 1987, JAMA.

[214]  W. Shipley,et al.  Invasive bladder carcinoma. The importance of initial transurethral surgery and other significant prognostic factors for improved survival with full‐dose irradiation , 1987, Cancer.

[215]  M. Rotman,et al.  Treatment of advanced bladder carcinoma with irradiation and concomitant 5‐fluorouracil infusion , 1987, Cancer.

[216]  W. Duncan,et al.  Primary radical radiotherapy for T3 transitional cell cancer of the bladder: an analysis of survival and control. , 1986, International journal of radiation oncology, biology, physics.

[217]  W. Duncan,et al.  The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. , 1986, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[218]  B. Nilsson,et al.  Irradiation therapy with multiple small fractions per day in urinary bladder cancer. , 1985, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[219]  W. Shipley,et al.  Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival. , 1985, The Journal of urology.

[220]  P. Elson,et al.  Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinomas of the urinary tract. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[221]  H. Herr.  Preoperative irradiation with and without chemotherapy as adjunct to radical cystectomy. , 1985, Urology.

[222]  D. Skinner,et al.  Contemporary cystectomy with pelvic node dissection compared to preoperative radiation therapy plus cystectomy in management of invasive bladder cancer. , 1984, The Journal of urology.

[223]  J. Montie,et al.  Radical cystectomy without radiation therapy for carcinoma of the bladder. , 1984, The Journal of urology.

[224]  M. Soloway,et al.  A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A national bladder cancer collaborative group a study , 1983, Cancer.

[225]  S. Johansson,et al.  A prospective randomized study of preoperative irradiation with cystectomy or cystectomy alone for invasive bladder carcinoma. , 1983, European urology.

[226]  W. Hop,et al.  Carcinoma of the urinary bladder T3NxMo treated by preoperative irradiation followed by simple cystectomy. , 1982, International journal of radiation oncology, biology, physics.

[227]  D. Skinner,et al.  High dose, short course preoperative radiation therapy and immediate single stage radical cystectomy with pelvic node dissection in the management of bladder cancer. , 1982, The Journal of urology.

[228]  M. Boileau,et al.  Bladder carcinoma: results with preoperative radiation therapy and radical cystectomy. , 1980, Urology.

[229]  I. Bross,et al.  Five‐year follow‐up results of a collaborative study of therapies for carcinoma of the bladder , 1977, Journal of surgical oncology.

[230]  A. Morrison,et al.  Epidemiology of bladder cancer. , 1992, Hematology/oncology clinics of North America.

[231]  H. Withers,et al.  Four R's of radiotherapy , 1975 .

[232]  D. Byar,et al.  Results of a clinical trial of surgery and radiation in stages II and 3 carcinoma of the bladder. , 1972, The Journal of urology.

[233]  M. Blichert-toft,et al.  Congenital patient urachus and acquired variants. Diagnosis and treatment. Review of the literature and report of five cases. , 1971, Acta chirurgica Scandinavica.

[234]  D. Wallace.  Cancer of the bladder. , 1968, The American journal of roentgenology, radium therapy, and nuclear medicine.

[235]  P. Magee,et al.  Carcinogenic nitroso compounds. , 1967, Advances in cancer research.

[236]  C. Cuccia,et al.  Clinical impressions in 100 consecutive cases of carcinoma of the urinary bladder treated by supervoltage. , 1957, Transactions. American Urological Association. Southeastern Section.

[237]  B. S. Barringer.  Twenty-five years of radon treatment of cancer of the bladder. , 1947, Journal of the American Medical Association.